The role of intestinal ultrasound with colour Doppler in predicting the response to biologic therapy in inflammatory bowel disease patients

被引:0
|
作者
El-Nady, Mohamed Ali [1 ]
El-Hefny, Nour Eldeen [2 ]
Fathy, Hayam [2 ]
Ali, Wageeh [3 ]
Ashmawy, Ahmed Mohammed [2 ]
机构
[1] Cairo Univ, Fac Med, Dept Internal Med, Cairo, Egypt
[2] Assiut Univ, Fac Med, Dept Internal Med, Hepatogastroenterol Unit, Assiut, Egypt
[3] Assiut Univ, Fac Med, Radiol Dept, Assiut, Egypt
关键词
inflammatory bowel disease; ultrasound; Doppler; intestinal wall;
D O I
10.5114/pg.2023.132932
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction:Inflammatory bowel disease patients are exposed to frequent procedures and hospital admissions as well as recurrent need for radiological examinations with a high risk of exposure to radiation and contrast.Aim: Our objective was to evaluate the role of a combination of both intestinal ultrasound (IUS) and colour Doppler with different parameters for monitoring changes in inflammation over time and to reveal their potential role in the assessment of response to biologic therapy in inflammatory bowel disease (IBD) patients.Material and methods: Before the induction of biological therapy, IUS together with colour Doppler of the intestine was conducted. Response to therapy was defined following the international guidelines.Results: A total of 45 patients with histopathological diagnosis of IBD were enrolled in the study. All patients received biological therapy and were assessed for response after 3 months. Out of those patients, 34 (75.6%) had good response while 11 (24.4%) failed to respond to the treatment. Our findings point to a strong association between bowel wall thickening (BWT) and serum albumin, erythrocyte sedimentation rate (ESR), and c-reactive protein (CRP). The overall sensitivity of IUS varied from 54 to 93% when evaluating bowel affection, with a specificity of 97-100%, in comparison to our results, which showed a sensi-tivity of 64-74% and specificity of 79-82%. Doppler parameters could predict the response to the biologic therapy in IBD patients. Conclusions: Intestinal ultrasound and colour Doppler provide a safe, non-invasive way to monitor changes in inflammation and blood flow in the digestive tract.
引用
收藏
页码:416 / 422
页数:7
相关论文
共 50 条
  • [41] Changes in gut microbiota of patients with inflammatory bowel disease receiving biologic therapy
    Tai, W. C.
    Yao, C. C.
    Tsai, Y. -C.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I2153 - I2153
  • [42] VACCINATIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS RECEIVING BIOLOGIC THERAPY, ARE THEY BEING CONSIDERED?
    Chatten, K.
    Cornthwaite, L.
    Nixon, E.
    Goel, A.
    GUT, 2017, 66 : A243 - A244
  • [43] LOWER SUSTAINED PERTUSSIS CONCENTRATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON BIOLOGIC THERAPY
    Caldera, Freddy
    McCrone, Sue
    Garmoe, Christine A.
    Megna, Bryant W.
    Ley, Dana
    Reichelderfer, Mark
    Hayney, Mary S.
    GASTROENTEROLOGY, 2017, 152 (05) : S59 - S59
  • [44] Overuse of Tuberculosis Screening Practices in Patients With Inflammatory Bowel Disease on Biologic Therapy
    Vecchio, Eric
    Mao, Eric
    Fine, Sean
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S369 - S369
  • [45] Biologic therapy and the risk of herpes zoster among patients with inflammatory bowel disease
    Santella, Christina
    Bitton, Alain
    Filliter, Christopher
    Vutcovici, Maria
    Bessissow, Talat
    Lakatos, Peter
    Brassard, Paul
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 607 - 607
  • [46] Influence of biologic therapy on cardiovascular risk factors in patients with inflammatory bowel disease
    Roig, Clara Amiama
    Ferrer, Cristina Suarez
    Garcia, Jose Luis Rueda
    Cordon, Joaquin Poza
    Sanchez-Azofra, Maria
    Arranz, Eduardo Martin
    Diaz, Irene Gonzalez
    Costa, Carmen Amor
    Martin-Arranz, Maria Dolores
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2023, 46 (02): : 109 - 115
  • [47] BIOLOGIC THERAPY PREVENTS COVID RELATED COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS
    Nanah, Rama
    Almasri, Jehad
    Eltelbany, Ahmed
    Nanah, M. Housam
    Khoudari, George
    Nanah, Robana
    Hamid, Osama
    Regueiro, Miguel D.
    GASTROENTEROLOGY, 2023, 164 (06) : S534 - S534
  • [48] Factors Associated with Delays in Initiating Biologic Therapy in Patients with Inflammatory Bowel Disease
    Abadir, Alexander
    Troia, Angela
    Said, Hyder
    Tarugu, Spurthi
    Billingsley, Benjamin C.
    Sairam, Nathan
    Minchenberg, Scott B.
    Owings, Anna H.
    Parker, Adam M.
    Brousse, Brandon
    Carlyle, Alexander
    Owens, Bobby R.
    Hosseini-Carroll, Pegah
    Galeas-Pena, Michelle
    Frasca, Joseph
    Glover, Sarah C.
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (08) : 2796 - 2803
  • [49] ASSOCIATION OF BIOLOGIC THERAPY OVERLAP WITH THE RISK OF INFECTIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Kruger, Annie J.
    Dormont, Flavio
    Capit, Nicolas
    Schilsky, Samantha
    Roberts, Andrew
    Lin, Yong
    Badalamenti, Salvatore
    Wiekowski, Maria
    Bewtra, Meenakshi
    Colombel, Jean Frederic
    GASTROENTEROLOGY, 2024, 166 (05) : S1132 - S1133
  • [50] Intestinal ultrasound as a tool to assess treatment response in patients with Inflammatory Bowel Diseases
    Katsaros, M.
    Katsoula, A.
    Kalogirou, M.
    Paschos, P.
    Papagiannakis, P.
    Tsionis, T.
    Giouleme, O.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I682 - I683